Featured Research

from universities, journals, and other organizations

Discovery Of A 'Molecular Switch' Could Lead To New Ways Of Treating Infection

Date:
April 27, 2005
Source:
Imperial College London
Summary:
The discovery of a 'molecular switch' could lead to new ways of treating infections such as MRSA, and inflammatory diseases like arthritis.

The discovery of a 'molecular switch' could lead to new ways of treating infections such as MRSA, and inflammatory diseases like arthritis.

According to research published today in Nature, the team from Imperial College London and the University of California, San Diego, have identified an enzyme called IKKa, which can act as a 'brake' on an immune cell pathway responsible for regulating the body's response to infection and inflammation.

By inhibiting IKKa activity the researchers were able to increase the body's ability to fight off infection, but at the same time also increased the body's inflammatory response. They also found that IKKa inhibits activation of immune cells, and inhibits inflammation, a discovery which could lead to new ways of treating diseases such as arthritis.

Dr Toby Lawrence, a Wellcome Trust International Research Fellow from Imperial College London, based at the Kennedy Institute of Rheumatology, and lead author of the research, says: "The identification of this 'double-edged sword' could be of huge importance in how we deal with a number of major health issues, including MRSA. With antibacterial resistance on the rise, this development could provide doctors with a new way to stop infections without resorting to a cocktail of antibiotics.

"Although this is only a first step, the discovery could also help arthritis sufferers. By increasing IKKa activity we may be able to stop inflammation, and possibly develop a new treatment."

The team investigated the role of IKKa in inflammation and immunity by comparing the response of mice with a defective IKKa enzyme, compared to normal mice, when exposed to the pathogen Streptococcus. In the mice without IKKa, they found significantly increased killing of bacteria in sepsis and pneumonia, but found that inflammation was higher than the normal mice. This result led the team to believe that IKKa was a stop signal to limit the inflammatory response.


Story Source:

The above story is based on materials provided by Imperial College London. Note: Materials may be edited for content and length.


Cite This Page:

Imperial College London. "Discovery Of A 'Molecular Switch' Could Lead To New Ways Of Treating Infection." ScienceDaily. ScienceDaily, 27 April 2005. <www.sciencedaily.com/releases/2005/04/050427134835.htm>.
Imperial College London. (2005, April 27). Discovery Of A 'Molecular Switch' Could Lead To New Ways Of Treating Infection. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/04/050427134835.htm
Imperial College London. "Discovery Of A 'Molecular Switch' Could Lead To New Ways Of Treating Infection." ScienceDaily. www.sciencedaily.com/releases/2005/04/050427134835.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins